Emoxypine - Pharmasoft
Alternative Names: Emoxypine succinate; Ethylmethylhydroxypyridine Succinate; MEXIDOLLatest Information Update: 03 Mar 2025
At a glance
- Originator Pharmasoft
- Class Antidepressants; Antiglaucomas; Anxiolytics; Heart failure therapies; Nootropics; Pyridines; Small molecules
- Mechanism of Action Antioxidants; NF-E2-related factor 2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Anxiety disorders
- Phase III Attention-deficit hyperactivity disorder; Cerebral ischaemia; Ischaemic stroke
- Phase II Open-angle glaucoma
- No development reported Cognition disorders; Ischaemic heart disorders; Pancreatitis; Peptic ulcer
Most Recent Events
- 03 Mar 2025 Launched for Anxiety disorders in Russia (PO, Tablet)
- 05 Dec 2000 A study has been added to the Peptic Ulcer Disease therapeutic trials section
- 04 Dec 2000 Investigation in Peptic ulcer in Russia (Unknown route)